Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04291092 | Camrelizumab Combined With Local Treatment in NSCLC Patients With BM | unknown | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04755738 | Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer(MWA) | unknown | Phase 2 | 234 | Qianfoshan HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05034055 |
| Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer(SKYROCKET) |
| unknown |
| Phase 2 |
| 45 |
| Yonsei UniversityOTHER |
| 1 |
| Sep 5, 2021 |
| clinicaltrials |
| NCT05034133 | Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 20 | Beijing Haidian HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02736513 | Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | unknown | Phase 2 | 40 | Soroka University Medical CenterOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04943029 | Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC(NEOSUN) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT05024266 | Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma(TACT) | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04586465 | Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC(DYNAPET) | unknown | Phase 2 | 23 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT05016544 | Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT05005468 | A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.(CAMFA-L) | unknown | Phase 2 | 61 | Shanghai Chest HospitalOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04846452 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04998474 | FRAME-001 Personalized Vaccine in NSCLC | unknown | Phase 2 | 15 | Frame Pharmaceuticals B.V.INDUSTRY | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04985201 | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04982549 | A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC | unknown | Phase 2 | 35 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04988607 | Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC | unknown | Phase 2 | 90 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT04698941 | Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 29, 2021 | clinicaltrials |
| NCT04872634 | A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment(SNK_ASTER) | unknown | Phase 1 / Phase 2 | 24 | NKMAX Co., Ltd.INDUSTRY | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04970693 | A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | unknown | Phase 2 | 64 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04968002 | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03439215 | PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer(PFROST) | unknown | Phase 2 | 20 | Fondazione Ricerca TraslazionaleOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT04237805 | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 1 / Phase 2 | 280 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04952168 | Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC | unknown | Phase 2 | 26 | Yuan ChenOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04941417 | Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients | unknown | Phase 2 | 60 | Peking Union Medical CollegeOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04541251 | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | unknown | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04933175 | Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer | unknown | Phase 2 | 50 | Liu ZhenhuaOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT03447678 | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.(PEOPLE) | unknown | Phase 2 | 65 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04905550 | Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC | unknown | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04890795 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 237 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT04884009 | A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 106 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04828395 | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer(F&C) | unknown | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04882345 | Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment(ACTIVE) | unknown | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 0 | May 11, 2021 | clinicaltrials |
| NCT04874844 | JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety | unknown | Phase 2 / Phase 3 | 420 | Beijing Dongfang Biotech Co., Ltd.INDUSTRY | 0 | May 10, 2021 | clinicaltrials |
| NCT04304248 | Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer(NeoTAP01) | unknown | Phase 2 | 30 | Hao LongOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT04865705 | Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer | unknown | Phase 2 | 33 | West China HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04833205 | Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer | unknown | Phase 2 | 30 | Hui BuOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT04725448 | Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | unknown | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | unknown | Phase 1 / Phase 2 | 96 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT04790539 | a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 71 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT02927340 | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | unknown | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00643318 | CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer | unknown | Phase 2 | 40 | Accuray IncorporatedINDUSTRY | 2 | Mar 5, 2021 | clinicaltrials |
| NCT04762030 | Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study | unknown | Phase 2 | 39 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04757779 | A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer | unknown | Phase 2 | 40 | First People's Hospital of HangzhouOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04740021 | Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 46 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2021source: clinicaltrials